C

CRISPR Therapeutics AG
D

CRSP

46.290
USD
-0.93
(-1.97%)
Market Closed
Volume
0
EPS
-5
Div Yield
-
P/E
-15
Market Cap
3,942,434,034
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    F
    FATE
    -0.04500
    (-2.17%)
    2.02500 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.14 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.37 USD
    More
News

Title: CRISPR Therapeutics AG

Sector: Healthcare
Industry: Biotechnology
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.